Tumor Debulking
Peritoneal Deciduoid Mesothelioma
International Journal of Surgical Pathology 2017 January [Epub ahead of print] [Link] Dominiak N, Graybill W, Gunning W, Richardson MS, Spruill LS Abstract This report highlights a diagnostically challenging case of diffuse deciduoid mesothelioma occurring in the peritoneum of a 25-year-old woman, 8 months postpartum. Optimally debulked tumor consisted of sheets of polygonal cells arranged…
Read MoreMentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases
European Journal of Surgical Oncology 2016 November [Epub ahead of print] [Link] Chang KH, Kazanowski M, Staunton O, Cahill RA, Moran BJ, Shields C, Mulsow J Abstract BACKGROUND: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are considered standard of care for pseudomyxoma peritonei (PMP) and selected patients with colorectal peritoneal metastases (CPM) or peritoneal…
Read MoreMalignant pleural mesothelioma with lacrimal gland metastasis
Acta Ophthalmologica 2016 December 9 [Epub 2016 July 16] [Link] Hanafi H, Verdijk RM, Paridaens D Abstract PURPOSE: To describe a rare clinical case of biopsy-proven metastatic mesothelioma of the lacrimal gland which responded well to chemo and radiation therapy. METHODS: Interventional case report. RESULTS: A 55-year-old woman with an untreated malignant biopsy-proven pleural mesothelioma…
Read MoreChest wall resection for mesothelioma recurrence after surgery
Asian Cardiovascular & Thoracic Annals 2016 November [Epub 2016 October 9] [Link] Bertoglio P, Fanucchi O, Ricciardi S, Chella A, Lucchi M, Mussi A Abstract Malignant pleural mesothelioma is an aggressive and usually fatal disease, and its optimal management is still under debate. Surgery for recurrent malignant mesothelioma has been reported rarely in highly selected…
Read MoreImaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group
Lung Cancer 2016 November [Epub 2016 September 5] [Link] Armato SG, Blyth KG, Keating JJ, Katz S, Tsim S, Coolen J, Gudmundsson E, Opitz I, Nowak AK Abstract Imaging plays an important role in the detection, diagnosis, staging, response assessment, and surveillance of malignant pleural mesothelioma. The etiology, biology, and growth pattern of mesothelioma present…
Read MoreA Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
Journal of Thoracic Oncology 2016 November [Epub 2016 July 20] [Link] Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA Abstract There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting…
Read MoreMalignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab
Journal of Thoracic Oncology 2016 November [Epub 2016 August 17] [Link] Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R Abstract NTRODUCTION: The functional aspects of programmed death 1 (PD-1) and PD ligand 1 (PD-L1) immune checkpoints in malignant mesothelioma have not…
Read MorePreclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET
Molecular Cancer Therapeutics 2016 October 19 [Epub ahead of print] [Link] Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt A, Tinianow J, Gupta N2, Li D, Firestein R, Marik J, Scales SJ, Williams SP Abstract Antibody-drug conjugates (ADCs) use monoclonal antibodies (mAb) as vehicles to deliver potent cytotoxic drugs selectively to tumor cells expressing…
Read MoreSystemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy
Molecular Pharmaceutics 2016 October 14 [Epub ahead of print] [Link] Abu Lila AS, Fukushima M, Huang CL, Wada H, Ishida T Abstract Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene.…
Read MoreOptimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study
Acta Oncologica 2016 October 12 [Epub ahead of print] [Link] Botticella A, Defraene G, Nackaerts K, Deroose CM, Coolen J, Nafteux P, Peeters S, Ricardi U, De Ruysscher D Abstract BACKGROUND: The gross tumor volume (GTV) definition for malignant pleural mesothelioma (MPM) is ill-defined. We therefore investigated which imaging modality is optimal: computed tomography (CT)…
Read More